MX2012006206A - Preparaciones combinacion comprendiendo exosomas y corticosteroide. - Google Patents

Preparaciones combinacion comprendiendo exosomas y corticosteroide.

Info

Publication number
MX2012006206A
MX2012006206A MX2012006206A MX2012006206A MX2012006206A MX 2012006206 A MX2012006206 A MX 2012006206A MX 2012006206 A MX2012006206 A MX 2012006206A MX 2012006206 A MX2012006206 A MX 2012006206A MX 2012006206 A MX2012006206 A MX 2012006206A
Authority
MX
Mexico
Prior art keywords
exosomes
corticosteroid
combination preparations
combination therapy
diseases
Prior art date
Application number
MX2012006206A
Other languages
English (en)
Inventor
Julio Reinecke
Peter Wehling
Original Assignee
Orthogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthogen Ag filed Critical Orthogen Ag
Publication of MX2012006206A publication Critical patent/MX2012006206A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se relaciona con composiciones farmacéuticas para terapia de combinación comprendiendo un corticosteroide y exosomas. La terapia de combinación referida permite el tratamiento de enfermedades como artrosis, artritis reumatoide y/o enfermedades degenerativas de la columna vertebral.
MX2012006206A 2009-12-10 2010-12-10 Preparaciones combinacion comprendiendo exosomas y corticosteroide. MX2012006206A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009057495 2009-12-10
PCT/EP2010/069426 WO2011082950A1 (de) 2009-12-10 2010-12-10 Kombinationspräparate mit exosomen und corticosteroid

Publications (1)

Publication Number Publication Date
MX2012006206A true MX2012006206A (es) 2012-06-28

Family

ID=43707934

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012006430A MX2012006430A (es) 2009-12-10 2010-12-10 Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide.
MX2012006206A MX2012006206A (es) 2009-12-10 2010-12-10 Preparaciones combinacion comprendiendo exosomas y corticosteroide.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012006430A MX2012006430A (es) 2009-12-10 2010-12-10 Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide.

Country Status (22)

Country Link
US (3) US8828946B2 (es)
EP (2) EP2437747B8 (es)
JP (2) JP5984674B2 (es)
KR (2) KR101786444B1 (es)
CN (2) CN102655868A (es)
AU (2) AU2010340999B2 (es)
BR (2) BR112012014066A2 (es)
CA (2) CA2781576C (es)
CY (2) CY1118081T1 (es)
DE (1) DE202009017772U1 (es)
DK (2) DK2437747T3 (es)
ES (2) ES2594896T3 (es)
HR (2) HRP20161268T1 (es)
HU (2) HUE030460T2 (es)
LT (2) LT2437747T (es)
MX (2) MX2012006430A (es)
PL (2) PL2437748T3 (es)
PT (2) PT2437747T (es)
RS (2) RS55217B1 (es)
RU (2) RU2557897C2 (es)
SI (2) SI2437748T1 (es)
WO (2) WO2011082950A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170189475A9 (en) * 2009-12-10 2017-07-06 Orthogen Ag Combination preparation comprising a cytokine antagonist and corticosteroid
DE102012019088A1 (de) * 2012-09-28 2014-04-03 Orthogen Ag Antibakterielle Arzneimittelpräparate
CN104673749B (zh) * 2015-02-12 2017-10-20 江苏大学 一种粒细胞样髓源性抑制细胞来源exosomes及其应用
WO2017080669A1 (en) * 2015-11-13 2017-05-18 Orthogen Ag Pharmaceutical preparation effective in age-related disorders
CR20190139A (es) * 2016-08-17 2019-06-03 Orthogen Ag Preparación farmacéutica anti envejecimiento
EP3500278A4 (en) 2016-08-19 2020-04-01 Calimmune, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS USING A RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS
WO2018056481A1 (ko) * 2016-09-23 2018-03-29 ㈜프로스테믹스 면역 억제 및 항염증성 조성물
US11958886B2 (en) 2016-12-07 2024-04-16 University Of Florida Research Foundation, Incorporated IL-1RA cDNAs
CN108175759B (zh) * 2016-12-08 2021-03-19 暨南大学 一种抗肿瘤靶向给药系统及其制备方法与应用
EA038300B1 (ru) * 2017-04-18 2021-08-06 Юниверсити Оф Флорида Рисерч Фаундейшен, Инкорпорейтед Кднк il-1ra
CN108619114B (zh) * 2018-05-02 2020-08-11 东南大学 一种负载地塞米松的巨噬细胞源微囊泡及其制备方法和应用
CN109078171A (zh) * 2018-09-10 2018-12-25 因之彩生物科技（武汉）有限公司 一种外用组合物及其应用以及外用治疗剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2793159A (en) * 1955-03-09 1957-05-21 Upjohn Co Stable hydrocortisone solution
KR0148009B1 (ko) 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
IL125552A0 (en) 1996-02-09 1999-03-12 Amgen Inc Composition comprising interleukin-1 inhibitor and controlled release polymer
DE69726884T2 (de) * 1997-02-06 2004-06-03 Genetics Institute, LLC, Cambridge Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
US6623472B1 (en) 1997-08-16 2003-09-23 Orthogen Gentechnologic. Gmbh Method for inducing therapeutically-effective proteins
DE19903876B4 (de) 1999-02-01 2006-09-28 Orthogen Gentechnologie Gmbh Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten
DE10213780A1 (de) 2002-03-22 2003-11-27 Orthogen Ag Verfahren und Mittel zur Herstellung therapeutisch interessanter Blutzusammensetzungen
WO2006007529A2 (en) 2004-07-01 2006-01-19 University Of Pittsburgh Of The Commonwealth System For Higher Education Immunosuppressive exosomes
DE102004036840B4 (de) 2004-07-29 2012-04-19 Orthogen Ag Verfahren und Mittel zur Gewinnung von thrombocytenreichem Plasma
TW200740441A (en) * 2005-06-17 2007-11-01 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
US20080207577A1 (en) 2005-07-11 2008-08-28 Astrazeneca Ab Combination I
US7292185B2 (en) * 2005-10-04 2007-11-06 Csi Wireless Inc. Attitude determination exploiting geometry constraints
NZ568694A (en) * 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
DE102006005016A1 (de) 2006-02-03 2007-08-16 Orthogen Ag Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
JP5984674B2 (ja) 2016-09-06
BR112012013888A2 (pt) 2017-03-07
LT2437747T (lt) 2016-10-25
CA2781576A1 (en) 2011-07-14
SI2437747T1 (sl) 2016-12-30
CN102655868A (zh) 2012-09-05
JP2013513583A (ja) 2013-04-22
CN102652020A (zh) 2012-08-29
EP2437748B8 (de) 2016-10-19
RU2557897C2 (ru) 2015-07-27
PL2437747T3 (pl) 2017-01-31
CA2781223C (en) 2016-02-16
CY1118044T1 (el) 2017-05-17
LT2437748T (lt) 2016-11-10
EP2437748A1 (de) 2012-04-11
US9724391B2 (en) 2017-08-08
US20120237525A1 (en) 2012-09-20
SI2437748T1 (sl) 2016-12-30
US20190038719A1 (en) 2019-02-07
HUE029979T2 (en) 2017-04-28
RU2526161C2 (ru) 2014-08-20
AU2010341000B2 (en) 2014-08-14
EP2437747B1 (de) 2016-08-31
JP2013513582A (ja) 2013-04-22
WO2011082951A1 (de) 2011-07-14
DK2437748T5 (en) 2016-12-05
RS55251B1 (sr) 2017-02-28
CA2781576C (en) 2016-02-09
HRP20161268T1 (hr) 2016-11-04
KR20120109542A (ko) 2012-10-08
JP5907886B2 (ja) 2016-04-26
ES2594896T3 (es) 2016-12-23
MX2012006430A (es) 2012-07-30
RS55217B1 (sr) 2017-02-28
ES2594766T3 (es) 2016-12-22
US20120237587A1 (en) 2012-09-20
EP2437747A1 (de) 2012-04-11
US8828946B2 (en) 2014-09-09
AU2010341000A1 (en) 2012-06-21
HUE030460T2 (en) 2017-05-29
EP2437748B1 (de) 2016-08-31
US20130164303A2 (en) 2013-06-27
DE202009017772U1 (de) 2011-04-21
PT2437748T (pt) 2016-10-14
AU2010340999B2 (en) 2014-08-14
KR20120107108A (ko) 2012-09-28
AU2010340999A1 (en) 2012-06-21
US10537614B2 (en) 2020-01-21
CA2781223A1 (en) 2011-07-14
BR112012014066A2 (pt) 2017-04-04
EP2437747B8 (de) 2016-10-19
WO2011082950A1 (de) 2011-07-14
RU2012128776A (ru) 2014-01-20
CN107096031A (zh) 2017-08-29
RU2012128877A (ru) 2014-01-20
DK2437747T3 (en) 2016-10-24
HRP20161279T1 (hr) 2016-12-02
DK2437748T3 (en) 2016-10-24
PL2437748T3 (pl) 2017-09-29
CY1118081T1 (el) 2017-06-28
PT2437747T (pt) 2016-10-18
KR101786444B1 (ko) 2017-10-18

Similar Documents

Publication Publication Date Title
MX2012006206A (es) Preparaciones combinacion comprendiendo exosomas y corticosteroide.
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
TN2015000278A1 (en) Autotaxin inhibitors
MX2020001555A (es) Preparaciones terapéuticas de glicanos y métodos relacionados con estas.
GB201209613D0 (en) New compounds
NZ708727A (en) Conjugate compounds
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
GB201118656D0 (en) New compounds
IN2013CN01340A (es)
MX352661B (es) Moduladores novedosos de benzopiran cinasa.
IN2012DN00971A (es)
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
TN2011000647A1 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria
UA107550C2 (uk) Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
MY170604A (en) Inhibitors of apoptosis and uses thereof
AU2012280776B2 (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
EP2528440A4 (en) SUBSTITUTED NORINDEN ISOCHINOLINE, SYNTHESIS THEREOF AND METHOD OF USE THEREOF
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
IN2014DN09437A (es)
IN2014DN03010A (es)
WO2009140418A3 (en) Compositions and methods for treating arthritis and/or diseases involving cartilage degeneration
TN2011000587A1 (en) Solid pharmaceutical compositions and processes for their production

Legal Events

Date Code Title Description
FG Grant or registration